美国 · 平台与数据 · The Motley Fool

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

来源：The Motley Fool · 美国 1 小时前

The company's gene-editing-focused platform looks promising.

在 The Motley Fool 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

推荐阅读

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double